Tennessee Senate Bill SB2499

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 4; Title 56 and Title 71, relative to the coverage of long-acting injectable drugs for the treatment or prevention of human immunodeficiency virus.

Impact

If enacted, SB2499 will update existing healthcare laws to ensure that long-acting injectable drugs for HIV treatment are classified and reimbursed appropriately under both medical and pharmacy benefits. The aim is to streamline access to these necessary medications for individuals enrolled in TennCare, thus potentially improving health outcomes for those living with or at risk of HIV. This change is crucial as it not only enhances the accessibility of relevant treatments but also aligns Tennessee's healthcare policies with modern medical practices.

Summary

Senate Bill 2499 aims to amend the Tennessee Code to include provisions for the coverage of long-acting injectable drugs specifically for the treatment or prevention of human immunodeficiency virus (HIV). The bill mandates that managed care organizations (MCOs) and pharmacy benefits managers (PBMs) provide reimbursement for these injectable treatments when they are administered in various healthcare settings such as pharmacies, clinics, and hospitals. This legislative effort is significant as it emphasizes the inclusion of HIV treatment options under health coverage plans, reflecting a growing recognition of the need for comprehensive healthcare solutions to combat this virus.

Sentiment

The sentiment surrounding SB2499 appears generally supportive, particularly among health advocacy groups and organizations focused on HIV awareness and treatment. By facilitating coverage for long-acting injectables, the bill is seen as a positive step towards improving healthcare services for vulnerable populations. There may also be opposition from stakeholders concerned about the implementation costs for MCOs and PBMs, but overall, the conversation seems to lean towards recognizing the importance of providing comprehensive HIV treatment options.

Contention

While SB2499 is largely welcomed, notable points of contention may arise regarding the financial implications for managed care organizations and how the reimbursement structure is implemented. Some critics might express concerns about the feasibility of these changes and whether they could lead to higher costs for healthcare providers. Additionally, discussions may focus on ensuring equitable access for all patients, as some might worry that reimbursement policies could inadvertently limit availability or lead to disparities in treatment access across different regions.